Join our daily newsletter At The Bell to receive exclusive market insights
- Neurotech International (NTI) has received promising early results from testing on the first 40 cannabis samples from Dolce Cann Global
- Around half the samples from Dolce have now been tested, with final results expected in early September
- The samples so far have shown elevated levels of cannabinoids with either known or potential therapeutic benefits
- Neurotech will commence in-vitro testing (using human derived cell lines) in September, using the test results to determine the key priority strains
- The current research is an important first step in the potential partnership between Neurotech and Dolce Cann Global in the development of novel treatments for neurological conditions
- Neurotech International’s share price spiked at open but has plummeted since — closing Friday’s session 18.8 per cent lower at 1.3 cents per share
Neurotech International (NTI) has received promising early results from testing on the first 40 cannabis samples from Dolce Cann Global.
Strong stuff
The samples showed a “wide cannabinoid profile” with levels of CBDA up to approximately 12 per cent. CBDA is a compound known to help with anxiety, nausea and inflammation.
The samples also contained “rarer” cannabinoids such as CBGA, CBG and THCA, which are for the most part still under investigation as to their potential medicinal applications.
Importantly, the samples contained less than 0.5 per cent THC — the ingredient in cannabis associated with the “high” sensation — so they may be more easily processed for medicinal purposes.
Cann can
NTI is conducting the testing through ACS Laboratories. Around half the samples from Dolce Cann Global have been tested, with final results expected in early September.
The research will underpin NTI’s decision on the option to acquire an exclusive worldwide licence to utilise Dolce’s proprietary cannabis strains.
Neurotech Chairman Mark Davies says the early results from ACS’ assessment are promising so far.
“Samples to date contain significant amounts of the cannabinoid CBDA, which is shown to have promise in treating inflammation and anxiety as well as neuro-protection, and our samples also contain an array of “rare” cannabinoids in their native form, such as THCA and CBGA,” Mark said.
“These cannabinoids need further analysis to quantitate the levels as they were only recently discovered and there is not much research available on them yet,” he continued.
“Considering this analysis is just the starting point of our research […] we look forward to testing the lead candidates in-vitro if the remainder of ACS’ analysis is consistent with these early results,” he added.
Next steps
Neurotech will commence in-vitro testing (using human derived cell lines) in September, using the ACS test results to determine the key priority strains. The company is aiming to identify compounds to target autism and other neurological disorders.
According to NTI, CBDA is still somewhat poorly understood, but it has been shown to have anti-anxiety, antipsychotic and neuroprotective properties.
It has also been investigated for possible therapeutic benefits in a range of conditions including epilepsy, substance abuse and dependence, post-traumatic stress, depression, bipolar disorder, and Parkinson’s disease.
The current research is an important first step in the potential partnership between Neurotech and Dolce Cann Global in the development of novel treatments for neurological conditions.
Neurotech International’s share price spiked at open but has plummeted since — closing Friday’s session 18.8 per cent lower at 1.3 cents per share.
